An Open-label, Single-arm, Phase IV Study Assessing the Immunogenicity and Safety of ZOSTAVAX® at Minimum Release Specification Approaching Expiry Potency in Subjects ≥50 Years Old.

Trial Profile

An Open-label, Single-arm, Phase IV Study Assessing the Immunogenicity and Safety of ZOSTAVAX® at Minimum Release Specification Approaching Expiry Potency in Subjects ≥50 Years Old.

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs Varicella zoster virus vaccine live (Primary)
  • Indications Herpes zoster
  • Focus Pharmacodynamics
  • Sponsors sanofi pasteur MSD
  • Most Recent Events

    • 03 Jul 2012 Planned number of patients 95 added as reported by European Clinical Trials Database.
    • 09 Dec 2008 Actual end date (Oct 2008) added as reported by ClinicalTrials.gov.
    • 09 Dec 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top